Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

Meredith McKean,Gerald Steven Falchook,Johanna C. Bendell,Babar Bashir,Neil Palmisiano,Roshawn Watson,Mary-Anne McKenna,Carly T. Campbell,D. Smethurst,Phil Jeffrey,Julius Kirui,Hendrik-Tobias Arkenau,Elisa Fontana

Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

2021

Meredith McKean
Gerald Steven Falchook
Johanna C. Bendell
Babar Bashir
Neil Palmisiano
Roshawn Watson
Mary-Anne McKenna
Carly T. Campbell
D. Smethurst
Phil Jeffrey
Julius Kirui
Hendrik-Tobias Arkenau
Elisa Fontana

TPS2668Background: BT8009 is a Bicycle Toxin Conjugate (BTC), a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting Nectin-4 tumor antigen, linked to cytotoxin ...

Keywords:

Nectin
Cancer research
in patient
Bicyclic molecule
Toxin
Peptide
Medicine
Conjugate
Tumor antigen
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations